Literature DB >> 8480499

Cascade system activation in shock.

A Bengtsson1.   

Abstract

Trauma and sepsis activate different cascade systems. Activation of the coagulation and clotting systems, of the kinin-kallikrein system and of the complement system are important etiological mechanisms behind development of the adult respiratory distress syndrome (ARDS) and multisystem organ failure (MOF) after extensive trauma or severe septic situations. Activation of complement with the release of anaphylatoxins and terminal complement complexes is associated with increased mortality and development of ARDS and MOF after major surgery and in situations of septic shock. The anaphylatoxins have potent vascular properties and they activate leukocytes. Their effects on the leukocytes lead to the release of free oxygen radicals, different lysosomal enzymes and cytokines, leukotrienes and histamine. All these inflammatory mediators may, if released in extensive amounts, induce microvascular injury and interstitial edema. If this process takes place in the lung, ARDS may develop and if other organs, i.e the liver and the kidneys, are involved, MOF may be the result.

Entities:  

Mesh:

Year:  1993        PMID: 8480499     DOI: 10.1111/j.1399-6576.1991.tb05065.x

Source DB:  PubMed          Journal:  Acta Anaesthesiol Scand Suppl        ISSN: 0515-2720


  3 in total

1.  Impairment of bacterial clearance induced by norepinephrine infusion in rabbits.

Authors:  T Koch; S Heller; K van Ackern; H G Schiefer; H Neuhof
Journal:  Intensive Care Med       Date:  1996-07       Impact factor: 17.440

2.  Transcriptome characterization by RNA-Seq reveals the involvement of the complement components in noise-traumatized rat cochleae.

Authors:  M Patel; Z Hu; J Bard; J Jamison; Q Cai; B H Hu
Journal:  Neuroscience       Date:  2013-05-30       Impact factor: 3.590

Review 3.  Hypersensitivity reactions to radiocontrast media: the role of complement activation.

Authors:  Janos Szebeni
Journal:  Curr Allergy Asthma Rep       Date:  2004-01       Impact factor: 4.919

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.